Pure Global
NCT00443053

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg Subcutaneously) for the Treatment of Patients With Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to Prevent Thromboembolic Complications
GlaxoSmithKline·Phase 3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Thrombosis, Venous
Drug/Device/Intervention
Fondaparinux 2.5mg or placebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
GlaxoSmithKline
Location
Sofia,Brno,Olomouc,Plzen,Praha 10,Praha 10,Praha 2,Praha 4,Praha 5,Praha 6,Ricany,Tabor,Saku,Tallinn,Tallinn,Tartu,Abbeville,Ales,Amiens,Annecy,Annonay,Arras,Bordeaux,Brest,Clermont Ferrand,Grenoble,M, Bulgaria,Czech,Estonia,France,Germany,Greece,Hungary,Israel,Italy,Latvia,Netherlands,Poland,Russian
Timeline & enrollment
Phase
Phase 3
Start date
Mar 01, 2007
End date
Jul 01, 2009
Enrollment
3002 participants
Primary outcome

Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47

Summary

To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of
 acute (recent) superficial thrombophlebitis.

ICD-10 classifications
Other venous embolism and thrombosisEmbolism and thrombosis of unspecified veinEmbolism and thrombosis of other specified veinsPerianal venous thrombosisArterial embolism and thrombosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00443053
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00443053 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 3002 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.